Is it time to target no evident disease activity (NEDA) in multiple sclerosis?
Tóm tắt
Từ khóa
Tài liệu tham khảo
Banwell, 2013, Editors׳ welcome and a working definition for a multiple sclerosis cure, Mult Scler Relat Disord, 2, 65, 10.1016/j.msard.2012.12.001
Bermel, 2010, Intramuscular interferon beta-1a therapy in patients with relapsing-remitting multiple sclerosis: a 15-year follow-up study, Mult Scler, 16, 588, 10.1177/1352458509360549
Cohen, 2010, Oral fingolimod or intramuscular interferon for relapsing multiple sclerosis, N Engl J Med, 362, 402, 10.1056/NEJMoa0907839
Cohen, 2012, Alemtuzumab versus interferon beta 1a as first-line treatment for patients with relapsing-remitting multiple sclerosis: a randomised controlled phase 3 trial, Lancet, 380, 1819, 10.1016/S0140-6736(12)61769-3
Coles, 2012, Alemtuzumab for patients with relapsing multiple sclerosis after disease-modifying therapy: a randomised controlled phase 3 trial, Lancet, 380, 1829, 10.1016/S0140-6736(12)61768-1
Coles, 2012, Alemtuzumab more effective than interferon beta-1a at 5-year follow-up of CAMMS223 clinical trial, Neurology, 78, 1069, 10.1212/WNL.0b013e31824e8ee7
Confavreux, 2000, Relapses and progression of disability in multiple sclerosis, N Engl J Med, 343, 1430, 10.1056/NEJM200011163432001
Dobson, 2014, Assessing treatment response to interferon-beta: is there a role for MRI?, Neurology, 82, 248, 10.1212/WNL.0000000000000036
Erbayat Altay, 2013, Reliability of classifying multiple sclerosis disease activity using magnetic resonance imaging in a multiple sclerosis clinic, JAMA Neurol, 70, 338, 10.1001/2013.jamaneurol.211
Giovannoni, 2010, Cerebrospinal fluid neurofilament: the biomarker that will resuscitate the ‘Spinal Tap’, Mult Scler, 16, 285, 10.1177/1352458510361358
Giovannoni, 2011, After the storm: neurofilament levels as a surrogate endpoint for neuroaxonal damage, Neurology, 76, 1200, 10.1212/WNL.0b013e3182143345
Giovannoni, 2011, Sustained disease-activity-free status in patients with relapsing-remitting multiple sclerosis treated with cladribine tablets in the CLARITY study: a post-hoc and subgroup analysis, Lancet Neurol, 10, 329, 10.1016/S1474-4422(11)70023-0
Hartung, 2011, Evolution of multiple sclerosis treatment: next generation therapies meet next generation efficacy criteria, Lancet Neurol, 10, 293, 10.1016/S1474-4422(11)70043-6
Havrdova, 2009, Effect of natalizumab on clinical and radiological disease activity in multiple sclerosis: a retrospective analysis of the Natalizumab Safety and Efficacy in Relapsing-Remitting Multiple Sclerosis (AFFIRM) study, Lancet Neurol, 8, 254, 10.1016/S1474-4422(09)70021-3
Kappos, 2010, A placebo-controlled trial of oral fingolimod in relapsing multiple sclerosis, N Engl J Med, 362, 387, 10.1056/NEJMoa0909494
Leray, 2010, Evidence for a two-stage disability progression in multiple sclerosis, Brain, 133, 1900, 10.1093/brain/awq076
Levesque, 2014, Converging goals of treatment for inflammatory Bowel disease, from clinical trials and practice, Gastroenterology
Miller, 2007, MRI outcomes in a placebo-controlled trial of natalizumab in relapsing MS, Neurology, 68, 1390, 10.1212/01.wnl.0000260064.77700.fd
Rio, 2009, Measures in the first year of therapy predict the response to interferon beta in MS, Mult Scler, 15, 848, 10.1177/1352458509104591
Scalfari, 2010, The natural history of multiple sclerosis: a geographically based study 10: relapses and long-term disability, Brain, 133, 1914, 10.1093/brain/awq118
Solomon, 2014, Review: treat to target in rheumatoid arthritis: fact, fiction, or hypothesis?, Arthritis Rheumatol, 66, 775, 10.1002/art.38323
Sormani, 2013, Scoring treatment response in patients with relapsing multiple sclerosis, Mult Scler, 19, 605, 10.1177/1352458512460605
Sormani, 2014, Treatment effect on brain atrophy correlates with treatment effect on disability in multiple sclerosis, Ann Neurol, 75, 43, 10.1002/ana.24018
Tuohy, 2014, Alemtuzumab treatment of multiple sclerosis: long-term safety and efficacy, J Neurol Neurosurg Psychiatry